0–2 hours
• Verify the signal immediately. Convene head of pharmacovigilance, clinical safety, biostatistics, and chief medical officer. Require raw data, case narratives, statistical analysis, and comparison to baseline liver‑failure incidence.
Reason: before acting publicly I must confirm this is a credible signal, not a coding artifact or confounder. But the threshold for escalation is low because patient harm is possible.

2–4 hours
• Notify General Counsel, Chief Compliance Officer, Head of Regulatory Affairs, and Chief Risk Officer.
• Form an internal “safety response task force.”
• Issue a document preservation notice across the company.
Reason: legal risk is now significant. Preserving documents prevents accusations of obstruction and ensures coordinated messaging.

4–6 hours
• Conduct rapid risk assessment:
– estimated attributable risk
– reversibility and early warning markers
– patient subgroups most at risk
– whether monitoring (e.g., liver enzyme tests) could mitigate harm
Reason: determines whether immediate prescribing guidance changes could reduce risk without pulling the drug.

6–8 hours
• Quietly engage external experts: hepatology specialist, independent drug safety statistician, and former FDA regulator.
Reason: independent validation strengthens credibility with regulators and the board.

8–12 hours
• Prepare a confidential briefing for FDA/EMA (or relevant regulators).
• Schedule an expedited safety discussion with FDA the next morning.
Reason: regulators react far more positively when companies self‑report early rather than after public disclosure.

12–16 hours
• Draft three parallel operational plans:

1. Label update + safety communication
2. Restricted prescribing / monitoring program
3. Temporary voluntary suspension
   Reason: we must be ready for multiple regulatory outcomes.

16–20 hours
• Meet with communications and investor relations teams.
• Draft two versions of messaging:
– regulatory safety disclosure
– earnings call statement
Reason: transparency must be controlled, consistent, and medically accurate.

20–24 hours
• Inform the board chair and lead independent director privately; send a preliminary briefing to all board members ahead of the meeting.
Reason: avoids blindsiding them and builds trust before the formal meeting.

Day 2

24–28 hours
• FDA/agency notification and request for urgent consultation.
• Share data and proposed interim mitigation (e.g., liver monitoring guidance).
Reason: early cooperation reduces enforcement risk and litigation exposure.

28–32 hours
• Internal medical team drafts a “Dear Healthcare Provider” letter and updated safety guidance pending regulatory input.
Reason: clinicians need actionable guidance quickly if risk is confirmed.

32–36 hours
• Hold the full board meeting.
I recommend:
– immediate voluntary disclosure to regulators
– rapid label update warning of liver failure risk
– physician monitoring guidance
– ongoing investigation
Reason: waiting exposes patients and the company to far greater liability. Deliberate delay after internal knowledge can create catastrophic legal and reputational consequences.

36–40 hours
• Align PR, medical affairs, legal, and regulatory on a single external narrative:
– patient safety first
– rare but serious risk identified
– proactive action taken
– continued access with monitoring while investigation continues
Reason: proactive transparency preserves trust with regulators, doctors, and patients.

40–44 hours
• Prepare internal employee communication from CEO explaining the situation and company response.
Reason: employees will hear rumors; clear leadership prevents morale collapse and leaks.

44–48 hours
• Finalize disclosure language for:
– regulatory submission
– healthcare provider communication
– earnings call statement
• Ensure pharmacovigilance teams begin enhanced monitoring and data collection immediately.

What I would say on the earnings call (core strategy)
• Acknowledge identification of a rare liver safety signal.
• Emphasize proactive reporting and cooperation with regulators.
• Explain estimated risk and mitigation steps (monitoring, guidance).
• Reinforce commitment to patient safety over short‑term revenue.

Key strategic reasoning

Patient safety
Failing to act immediately could lead to preventable liver failure cases during the delay period.

Legal liability
If internal knowledge exists and action is delayed, future lawsuits become dramatically stronger (punitive damages risk).

Regulatory relationship
FDA penalties are far harsher for concealment than for unexpected safety findings.

Financial reality
A 40% stock drop is likely regardless once the issue becomes known. Early transparency can shorten recovery time.

Reputation
Pharma companies that act quickly on safety signals often regain trust; those that delay face years of damage.

Board dynamics
Presenting a clear risk‑minimization plan reframes the choice from “protect stock price” to “limit long‑term catastrophic exposure.”

Net strategy
Move fast, disclose early, mitigate risk, control the narrative. The long‑term enterprise value is better protected by transparency than by delay.